



Avivagen



**KYM ANTHONY, C.E.O.
SEPTEMBER, 2020
VIV:TSXV VIVXF:OTCQB**

Forward Looking Statement

This presentation includes certain forward-looking statements that are based upon current expectations of management, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking, including those identified by the expressions “anticipate”, “become”, “believe”, “can”, “estimate”, “prospective”, “further”, “targeting”, “would” and similar expressions.

Statements about anticipated market activity in livestock, the potential outcome of current discussions with potential customers and regulators in various jurisdictions; the outcome of regulatory processes currently underway; the implications of trial results to Avivagen’s business; Avivagen’s growth plans for livestock and companion animal products; expectations with respect to the growth of the relationship with UNAHCO, increased orders from UNAHCO and the effects of the UNAHCO relationship on Avivagen’s business in general; Avivagen’s plan to achieve sales goals for its companion animal products; illustrations of the global opportunity for Avivagen; future applications; possible outcomes of milestones and discussions highlighted; future customer wins; path to sales an additional customer adoption of Avivagen’s companion animal products; and Avivagen’s technology extended into human health applications are all forward-looking statements.

These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Such Avivagen risks and uncertainties include, but are not limited to, the following: the accuracy of third party information included in this presentation; the perceived market opportunity and ongoing discussions with third parties and customers may not translate into orders for Avivagen’s products; Avivagen’s growth strategy may not be as successful as Avivagen anticipates; UNAHCO could stop or fail to increase its orders of Avivagen’s products and Avivagen may not realize the anticipated benefits from the UNAHCO relationship; Avivagen’s ability to continue as a going concern; the results of ongoing or future trials may not be positive or sufficiently positive, third parties may not perceive Avivagen’s trial as positively as Avivagen does; even if the results are positive, there is no guarantee that its products will be commercially successful or that requisite regulatory approvals will be obtained for new or existing applications; Avivagen may not be successful with future customer wins or in securing additional customer adoption for its companion animal products; Avivagen may not be successful in expanding its products to additional applications; milestones may not be achieved; unless specifically indicated otherwise, current discussions highlighted with various parties are non-binding and may not lead to binding relationships that have the anticipated results and Avivagen’s technology may not be expanded into or may not receive regulatory approvals for human applications.

Accordingly, you should not place undue reliance on forward-looking statements.

Please refer to the risk factors relating to Avivagen’s business as outlined by the latest Management’s Discussion and Analysis of Financial Condition and Results of Operations and other securities filings available at www.SEDAR.com.

Except as required by law, Avivagen Inc. assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

This presentation contains information about the markets in which Avivagen operates which has been obtained from third parties, as indicated throughout. Although Avivagen believes such information to be reasonable, Avivagen has not independently verified such information and does not represent as to its accuracy.

THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER TO SELL, AN INVITATION TO INDUCE AN OFFER, OR A SOLICITATION OF AN OFFER TO ACQUIRE THE SHARES OF THE CORPORATION IN ANY JURISDICTION.

OUR OxC-beta™ PRODUCT

What it is:

- Oxidized Beta Carotene

Properties:

- Supports Immune Defenses
- Reduces Inflammation

OxC-beta was Discovered, NOT Created

- Published Ubiquity Paper

Technology
Discovered at
the National
Research
Council



OUR BUSINESS MODEL IS TO FOCUS ON 3 DISCRETE MARKETS:

OxC-beta™
For
Livestock

OxC-beta™
For
Companion Animal

OxC-beta™
For
Human
Applications:
Nutraceutical

Each Represents a Tremendous Global Market Opportunity

OxC-beta™ FOR LIVESTOCK FEED

1B

Tonnes per year
of feedstock

>30%

Access to global
feed market through
current distribution
agreements



Massive Market Opportunity

UP TO 80% Of all Antibiotics are used as AGP's



2006

EU-wide ban on all AGP's



2017

FDA bans use of antibiotics considered "medically important" for animal weight gain



2019

Chick-Fil-A reaches 5- year goal to go NAE



2020

China announces country-wide ban of AGP's by July 2020

Antibiotic Resistance a Global Threat

2M
Infections



700,000
Deaths



\$10k–\$40k
More per
hospital stay



\$100T

AMR could cost the globe up to \$100 Trillion by 2050

Antibiotic resistance has potential to **create more economic damage than the 2008 financial crisis**

Massive Health and Economic Implications

COMPETITIVE PRODUCTS

Probiotics/Prebiotics:

- Mixed efficacy, storage requirements

Essential Oils:

- Old Technology, mixed efficacy, compliance difficulties

Zinc Oxide:

- Environmental issues, Banned in many countries

OxC-beta™
Represents a
Next Generation
Antibiotic
Alternative



Product Sales



UNAHCO: 18.1 tonnes purchased to date for swine; recently added poultry



MEXICO: 1st order March 2020 for 250 kgs, later increased to 2 tonnes



BRAZIL: Received approval June 2020, 1st sale August 2020



Product Sales



TAIWAN: 1st order October 2019, repeated monthly sales since



THAILAND: 1st order September 2018, repeated monthly sales since



MALAYSIA: 1st customer order December 2019



Recent Developments



BRAZIL: 3rd largest livestock feed market @69 mm tonnes, approved June 2020, distribution agreement with Look Chemicals, 1st sale August 2020



NEW ZEALAND: Very successful dairy trial with NZ Dairy Associationsales interest growing



COFCO BIOTECH: Agreement to assist VIV with approval in China in 2020



U.S.: Numerous trials completed across different species; others pending

Mexican market offers significant potential

36 mm tonne
annual market



- Two very positive tests of the use of OxC-beta™ Livestock in commercial dairy production
- Initial 350 kg order increased to 2 tonnes, with ongoing purchase discussions continuing with Melder and other producers
- Serious discussions with potential customers ongoing.

U.S. Producers closely monitoring Mexican use

Testing Proves Efficacy and Safety

35+

Clinical and Field trials



- Reduced bacteria
- Reduced somatic cell count
- Increased protein content of milk

- Improved gut health
- Reduced E.coli
- Better maternal, piglet health
- Improved performance

- Reduced C. perfringens
- Improved performance

Strong Competitive Advantages

Economics and Trial Results

Cost of OxC-beta:

- Comparable to antibiotics (AGPs)
- Competitive to other alternatives

Benefits of OxC-beta:

- Replace AGPs without losing performance
- Outperforms other alternatives
 - Effectiveness
 - Consistency
- +ve impact on overall health

Strong Competitive Advantages

OxC-Beta™ FOR COMPANION ANIMAL

North America



JV with Mimi's
Rock, forming
new company
Center Beach

China, Taiwan & Mexico



First Health Chews sales in
Taiwan in April 2019, first
sale to Pet Food
manufacturer in Taiwan,
Feb 2020

First Health Chews sales in
Chinese market in 2019

First Health Chews sales in
Mexico in March 2020

Capitalizing on Current Sales Initiatives

OxC-beta™ FOR HUMAN WELLNESS: NUTRACEUTICAL

Accelerating plans for commercial launch of its OxC-beta™ Technology for human use in response to COVID-19 Pandemic

Hired Bloom Burton & Co.'s strategic Consultancy Group in order to optimize launch of the product into the US market

Includes confirming regulatory path, commercial strategy and timing: No drug approvals required



Largest Global Opportunity



Investment Summary



Proven solution to replace antibiotic use in animal feeds and help ensure livestock health



Accelerating plans for commercial launch of OxC-beta™ as Nutraceutical



Partnership with Mimi's Rock (MIMI/TSXV) for Companion Animal product



Growing Sales Pipeline; recurring revenue from repeat orders



Experienced management team with ability to deliver results



Experienced Management & Board, Proven Track Record



Kym Anthony

CEO



Paul Mesburis

Director



Jeffrey Kraws

Chairman



Dr. Graham Burton

Director



Aubrey Dan

Director



David Hankinson

Director

Industry Specific Knowledge and Success





Avivagen



Investor Presentation • May 2020